Fungal infections biotech SCYNEXIS files for a $55 million IPO

By
A A A

SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, filed on Thursday with the SEC to raise up to $55 million in an initial public offering. The Durham, NC-based company, which was founded in 1999 and booked $17 million in research services and licensing revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

GeneralPencil_USETBASITE
GeneralPencil_USETBASITE            

Stocks

Referenced

Most Active by Volume

62,950,963
  • $47.02 ▲ 21.85%
23,884,831
  • $15.401 ▲ 0.40%
21,555,560
  • $3.44 ▲ 1.18%
17,058,150
  • $29.18 ▼ 0.98%
15,623,061
  • $36.43 ▲ 2.10%
15,570,559
  • $7.87 ▼ 1.63%
15,373,475
  • $74.8001 ▲ 1.48%
14,727,532
  • $32.659 ▲ 18.03%
As of 7/30/2014, 11:23 AM